Passage Bio to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) announced participation in two virtual investor conferences in March 2021. The first is the Barclay’s Global Healthcare Conference on March 10, at 4:10 p.m. ET, featuring a presentation format. The second event is the Stifel 3rd Annual CNS Day on March 31, at 10:00 a.m. ET, in a fireside chat format. Both events will be webcast live, with replays available for 30 days. Passage Bio focuses on gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania's Gene Therapy Program.

PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in March:

Barclay’s Global Healthcare Conference
Format: Presentation
Date: Wednesday, March 10, 2021
Time: 4:10 p.m. ET

Stifel 3^rd Annual CNS Day
Format: Fireside Chat
Date: Wednesday, March 31, 2021
Time: 10:00 a.m. ET

A live webcast of the presentation and fireside chat will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the Barclay's and Stifel presentations will be available for 30 days following the fireside chat.

About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com

FAQ

What are the dates for Passage Bio's upcoming investor conferences in March 2021?

Passage Bio will participate in the Barclay’s Global Healthcare Conference on March 10, 2021, and Stifel 3rd Annual CNS Day on March 31, 2021.

What time will Passage Bio's presentations take place during the investor conferences?

The presentation at the Barclay’s Global Healthcare Conference is at 4:10 p.m. ET, and the fireside chat at Stifel 3rd Annual CNS Day is at 10:00 a.m. ET.

Where can I watch Passage Bio's investor conference presentations?

The presentations will be available via live webcast on the Investors & Media section of Passage Bio’s website.

How long will the replays of Passage Bio's presentations be available after the events?

Replays of the presentations will be available for 30 days following the events.

What is Passage Bio's focus in the biotech industry?

Passage Bio focuses on developing gene therapies for rare, monogenic central nervous system disorders.